

## 5<sup>th</sup> Annual Symposium

# The Frontiers of Neuroscience: Feelings & Forgetting

Adelaide Convention Centre, North Terrace, Adelaide  
Thursday 26 October 2017

**FREE registration (email Lauren Nicotra: [symposium@bionomics.com.au](mailto:symposium@bionomics.com.au))**

Time	Speaker	Topic
<b>SESSION 1:</b>		
9.15	<b>Dr Deborah Rathjen</b> CEO & Managing Director, Bionomics	Welcome
9.30	<b>Professor Steve Williams</b> IoPPN Kings College London & Maudsley Hospital	MR Neuroimaging to Facilitate the Drug R&D Process - from Mouse to Man
10.00	<b>Dr Ann Hayes</b> The Ann Hayes Consultancy; formerly Director of CNS Therapeutic Research, GlaxoWellcome	Multiple Mechanisms for Pain – How Can We Improve the Chances of Success?
<b>10.30</b>	<b>MORNING TEA</b>	
<b>SESSION 2:</b>		
11.00	<b>Dr Richard Hargreaves</b> Corporate Vice President Neuroscience & Imaging, Celgene	Seeing the Problems and Devising Solutions for Neurodegenerative Disease
11.30	<b>Professor Ole Isacson</b> Professor of Neurology & Neuroscience, Harvard Medical School	Novel Concepts from Human Cell Biology and Genetics for Neurodegenerative Disease Treatments
12.00	<b>Dr Michael F Egan</b> Associate Vice President, Clinical Neuroscience, MSD	Development of BACE Inhibitors for the Treatment of Alzheimer's Disease
<b>12.30</b>	<b>LUNCH</b>	
<b>SESSION 3:</b>		
1.30	<b>Dr Paul Coleman</b> Executive Director, Discovery Chemistry, MSD	Discovery of Belsomra, a First-in-Class Orexin Antagonist for the Treatment of Insomnia
2.00	<b>Professor Alexander McFarlane</b> Director of the Centre for Traumatic Stress Studies, Professor of Psychiatry, University of Adelaide	The Importance of a Staging Approach to Psychiatric Illness in Understanding the Role of Biomarkers and Treatment Response
2.30	<b>Professor Paul Rolan</b> Director of Innovation, University of Adelaide	Innovation in Clinical Trial Design
<b>3.00</b>	<b>AFTERNOON TEA</b>	
<b>SESSION 4:</b>		
3.30	<b>Professor Malcolm Hopwood</b> Ramsay Health Care Professor of Psychiatry, University of Melbourne	PTSD: Treatment Opportunities
4.00	<b>Dr Sue O'Connor</b> VP Neuroscience, Bionomics	BNC210 – A Novel Therapeutic in Development for PTSD
4.30	<b>Mr Ben Thorner</b> Senior Vice President, Business Development & Licensing, MSD	Close
<b>4.45-5.45</b>	<b>NETWORKING WITH DRINKS &amp; CANAPES</b>	

